BioMarin Provides 2 Years Of Clinical Data In 6e13 vg/kg Dose From Ongoing Phase 1/2 Study In Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A At World Federation Of Hemophilia 2018 World Congress
Benzinga Newsdesk